Human 5-HT(1F) receptor-stimulated [35S]GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation

European Journal of Pharmacology

Volumn 352, Issue 1, 1998, Pages 117-124

  Wainscott, David B ^a   Johnson, Kirk W ^a   Phebus, Lee A ^a   Schaus, John M ^a   Nelson, David L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT(1F) receptor; 35S GTP S binding

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; DIHYDROERGOTAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; LY 302148; LY 306258; METHYSERGIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NARATRIPTAN; PLASMA PROTEIN; RIZATRIPTAN; SEROTONIN; SEROTONIN 1F RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); RECOMBINANT PROTEIN; SEROTONIN RECEPTOR; SULFUR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; EXTRAVASATION; GUINEA PIG; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIGEMINAL NERVE; ANIMAL; CAPILLARY PERMEABILITY; DOSE RESPONSE; DURA MATER; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD PROTEINS; CAPILLARY PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DURA MATER; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUINEA PIGS; HUMANS; MICE; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; SULFUR RADIOISOTOPES; TRIGEMINAL NERVE;

EID: 0031594977     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00336-7     Document Type: Article

References (31)

1. 1 receptor subtype coupled to the inhibition of adenylate-cyclase. Proc. Natl. Acad. Sci. USA 90, 408-412.
2. 1F receptor subtype: a comparison of the pharmacological profile to the human species homologue. Neuropharmacology 36, 569-576.
3. 35S]-GTPγS binding. Br. J. Pharmacol. 121, 1203-1209.
4. 1E-like" serotonin receptor expressed predominantly in hippocampus. J. Biol. Chem. 267, 19761-19764.
5. Bradford, M.M., 1976. A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
7. Connor, H.E., Feniuk, W., Beattie, D.T., North, P.C., Oxford, A.W., Saynor, D.A., Humphrey, P.P.A., 1997. Naratriptan: biological profile in animal models relevant to migraine. Cephalagia 17, 145-152.
8. De Lean, A., Hancock, A.A., Lefkowitz, R.J., 1982. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol. 21, 5-16.
9. 1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br. J. Pharmacol. 116, 2385-2390.
10. Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., Humphrey, P.P.A., 1994. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157-203.
11. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport 8, 2237-2240.
12. Lazareno, S., Farries, T., Birdsall, N.J.M., 1993. Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors M1-M4. Life Sci. 52, 449-456.
13. Lee, W.S., Moskowitz, M.A., 1993. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res. 626, 303-305.
14. 35S]thio)triphosphate binding. Mol. Pharmacol. 44, 115-123.
15. 1E-like rat and human 5-hydroxytryptamine receptor genes. Proc. Natl. Acad. Sci. USA 90, 2184-2188.
16. 1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br. J. Pharmacol. 121, 157-164.
17. 1B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater. Br. J. Pharmacol. 104, 3-4.
18. 1A receptors. Neuropharmacology 35, 119-121.
19. 1Dα receptor sites. Neuropharmacology 34, 235-237.
20. 1B/D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 36, 499-512.
21. Phebus, L.A., Johnson, K.W., Stengel, P.W., Lobb, K.L., Nixon, J.A., Hipskind, P.A., 1997. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci. 60, 1553-1561.
22. 35S]thio)triphosphate binding in rat brain membranes. Life Sci. 59, 659-668.
23. 1D receptor agonist, MK-462. Cephalagia 15, 205, Suppl. 14.
24. 1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anesthetized rats. Neuropharmacology 36, 525-533.
25. 35S]thio]triphosphate binding. Proc. Natl. Acad. Sci. USA 92, 7242-7246.
26. 1D receptor antagonist. Behav. Brain Res. 73, 157-161.
27. 1D receptor subtypes. J. Recept. Signal Transduction Res. 15, 199-211.
28. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47, 848-854.
29. 1Dβ receptors. Eur. J. Pharmacol. 314, 365-372.
30. Wieland, T., Jakobs, K.H., 1994. Measurement of receptor-stimulated guanosine-5′-O-(γ-thio)triphosphate binding by G proteins. Methods Enzymol. 237, 3-13.
31. 1D receptor antagonist GR127935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology 36, 83-91.